# Zanzalintinib

Source: https://onco.cc/drugs/zanzalintinib/  
OnCo record `zanzalintinib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Zanzalintinib is an experimental small-molecule drug from Exelixis in phase 3 trials for neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma, aimed at VEGF / VEGFR and MET.

## Summary

Zanzalintinib (XL092) is a small-molecule drug developed by Exelixis and Merck Sharp & Dohme. Its targets are VEGF / VEGFR and MET (the sponsor names MET/VEGFR/AXL/MER). The sponsor states: Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT06943755 (Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumours), NCT06082167 (Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma) and NCT07227402 (A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)), in neuroendocrine tumours, head and neck squamous cell carcinoma and renal cell carcinoma. The largest, NCT07227402, plans to enrol 904 participants with primary completion expected 2032-02-27. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Code: XL092
- Modality: small molecule
- Mechanism: Exelixis describes zanzalintinib as a next-generation tyrosine kinase inhibitor (TKI) targeting MET, VEGFR, AXL and MER receptors.

## Sources

- ClinicalTrials.gov: trials of Zanzalintinib: https://clinicaltrials.gov/search?intr=XL092
- Sponsor pipeline page: https://www.exelixis.com/pipeline/

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- targets: [MET](https://onco.cc/targets/met/), [VEGF / VEGFR](https://onco.cc/targets/vegf/)
- companies: [Exelixis](https://onco.cc/companies/exelixis/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)
- trials: [A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)](https://onco.cc/trials/nct07489495/), [A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)](https://onco.cc/trials/nct07227402/), [Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study](https://onco.cc/trials/nct07620574/), [NIMBLE-CRC: NeoImmunoModulation Before Leveraging Excision in Colorectal Rectal Cancer](https://onco.cc/trials/nct07677579/), [Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer](https://onco.cc/trials/nct05425940/), [Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma](https://onco.cc/trials/nct06082167/), [Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (](https://onco.cc/trials/nct07049926/), [Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease](https://onco.cc/trials/nct07750158/), [Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors](https://onco.cc/trials/nct06943755/)

---
JSON: https://onco.cc/api/v1/entities/zanzalintinib.json